Group 1 - The core point of the article is that Kanglong Chemical (SZ 300759) announced the completion of a share reduction plan by its shareholder, Xincheng Kangcheng, who reduced approximately 26.67 million shares, accounting for 1.50% of the company's total shares [1] - As of the report date, Kanglong Chemical's market capitalization is 52.7 billion yuan [2] - For the year 2024, Kanglong Chemical's revenue composition is primarily from scientific research and technical services, which accounts for 99.95%, while other businesses contribute only 0.05% [1]

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年9月4日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事萬璇女士及李家慶先生；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日在巨潮资讯网（www.c ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东减 持股份的预披露公告》（公告编号：2025-027）。公司持股 5%以上股东深圳市 信中康成投资合伙企业（有限合伙）（以下简称"信中康成"）计划自上述减持 公告披露之日起 15 个交易日（2025 年 6 月 10 日）后的 3 个月内以集中竞价交 易或大宗交易等深圳证券交易所认可的合法方式减持公司股份不超过 26,672,932 股（占公司总股本的 1.50%）。 公司于近日收到信中康成和其一致行动人深圳市信中龙成投资合伙企业（有 限合伙）（以下简称"信中龙成"）出具的告知函，获悉信中康成本次减持计划 已实施完毕，现将减持计划实施情况公告如下： 一、股东减持情况 证券代码：300759 证券简称：康龙化成 公告编号：2025-050 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东减持计划实施完成的公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 2. 股份分類 | 普通股 ...

Group 1 - The core viewpoint of the news is that 康龙化成 (Crown Bioscience) has shown a mixed performance in its recent financial results, with revenue growth but a significant decline in net profit due to previous year's investment gains [1][2] - For the six months ending June 30, 2025, the company reported revenue of 6.441 billion RMB, a year-on-year increase of 14.93% [1] - The net profit attributable to shareholders was 701 million RMB, a decrease of 37% compared to the same period last year, primarily due to the impact of large investment gains from the disposal of PROTEOLOGIX, INC. in the previous year [1] Group 2 - 中银国际 (BOCI) reported that 康龙化成's revenue in the first half of the year grew by 15%, driven mainly by contributions from the top 20 multinational pharmaceutical companies and the European market [2] - The core business segments, particularly laboratory services and CMC, maintained good growth, while clinical CRO stabilized, and the large molecule and cell gene therapy segments remained weak [2] - The company expects new orders to grow by over 10% year-on-year in the first half of 2025, with laboratory services and CMC growing by 10% and 20% respectively, and has added 9 new Phase III and commercialization projects [2]

Core Viewpoint - 康龙化成's recent financial performance shows a mixed picture with revenue growth but a significant decline in net profit due to prior year investment gains [1][2] Group 1: Financial Performance - 康龙化成 reported revenue of 6.441 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 14.93% [1] - The company's net profit attributable to shareholders was 701 million RMB, a decrease of 37% compared to the previous year, primarily due to substantial investment gains from the disposal of PROTEOLOGIX, INC. in the prior period [1] - Basic earnings per share were reported at 0.3984 RMB [1] Group 2: Business Segments and Growth - The revenue growth was driven by contributions from the top 20 multinational pharmaceutical companies and the European market [2] - Core business segments, particularly laboratory services and CMC, showed strong growth, while clinical CRO remained stable, and the large molecule and cell gene therapy segments continued to be weak [2] - New orders for the first half of 2025 increased by over 10% year-on-year, with laboratory services and CMC growing by 10% and 20% respectively, and the addition of 9 new Phase III and commercialization projects [2] Group 3: Future Outlook - The company maintains its full-year revenue growth guidance of 10% to 15%, with expectations for improved profit margins in the second half of the year due to CMC scale effects, stable contributions from laboratory services, and stabilization of clinical CRO pricing [2] - The large molecule and cell gene therapy segments are expected to continue to drag on profits in the short term, but there is potential for breakeven in the medium to long term [2]

Group 1 - The core transaction on September 1 involved a block trade of 1.3 million shares of Kanglong Chemical, with a transaction value of 40.417 million yuan, at a price of 31.09 yuan, representing a discount of 0.80% compared to the closing price of the day [2][3] - In the last three months, Kanglong Chemical has recorded a total of 9 block trades, with a cumulative transaction value of 271 million yuan [3] - The closing price of Kanglong Chemical on the day of the report was 31.34 yuan, reflecting an increase of 3.57%, with a daily turnover rate of 4.68% and a total trading volume of 2.052 billion yuan [3] Group 2 - The latest margin financing balance for Kanglong Chemical is 1.474 billion yuan, with an increase of 4.7021 million yuan over the past five days, representing a growth rate of 0.32% [4] - In terms of institutional ratings, one institution has provided a rating for the stock in the past five days, with the highest target price estimated by浦银国际证券 at 39.00 yuan, as reported on August 26 [4]

Group 1 - The core viewpoint of the news is that 康龙化成 (Crown Bioscience) has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit [1][2] - As of September 1, 康龙化成's stock price increased by 2.05% to 30.88 CNY per share, with a total market capitalization of 549.11 billion CNY and a trading volume of 6.28 billion CNY [1] - The company has experienced a year-to-date stock price increase of 21.10%, but a decline of 2.95% over the last five trading days [1] Group 2 - For the first half of 2025, 康龙化成 reported a revenue of 64.41 billion CNY, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 7.01 billion CNY [2] - The company has distributed a total of 17.94 billion CNY in dividends since its A-share listing, with 10.07 billion CNY distributed over the last three years [3] - As of June 30, 2025, the number of shareholders increased by 10.12% to 87,900, indicating growing interest in the company's stock [2][3]

机构评级来看，近5日共有2家机构给予该股评级，预计目标价最高的是浦银国际证券，8月26日浦银国 际证券发布的研报预计公司目标价为39.00元。（数据宝） 8月29日康龙化成大宗交易一览 康龙化成8月29日大宗交易平台出现一笔成交，成交量120.00万股，成交金额3601.20万元，大宗交易成 交价为30.01元，相对今日收盘价折价0.83%。该笔交易的买方营业部为机构专用，卖方营业部为中信证 券华南股份有限公司广州万博证券营业部。 进一步统计，近3个月内该股累计发生8笔大宗交易，合计成交金额为2.30亿元。 证券时报·数据宝统计显示，康龙化成今日收盘价为30.26元，上涨2.79%，日换手率为3.53%，成交额为 15.02亿元，全天主力资金净流入7505.21万元，近5日该股累计上涨0.53%，近5日资金合计净流出2.42亿 元。 两融数据显示，该股最新融资余额为14.57亿元，近5日增加848.06万元，增幅为0.59%。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） ...